Research programme: lung disorder therapeutics - OrPro Therapeutics

Drug Profile

Research programme: lung disorder therapeutics - OrPro Therapeutics

Alternative Names: ORP-100; recombinant modified human thioredoxin 1 - OrPro Therapeutics; Theradux

Latest Information Update: 30 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Jewish Medical and Research Center
  • Developer OrPro Therapeutics
  • Class Recombinant proteins
  • Mechanism of Action Thioredoxin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cystic fibrosis; Lung disorders

Most Recent Events

  • 27 Oct 2015 OrPro Therapeutics receives patent allowance for recombinant modified human thioredoxin 1 in Cystic fibrosis and other Lung disorders in USA
  • 09 Oct 2014 Preclinical development in Cystic fibrosis is ongoing in USA
  • 31 Jul 2012 OrPro Therapeutics receives SBIR grant from the National Institutes of Health for the development of ORP 100, a lead candidate from OrPro's lung disorder therapeutics research programme, in Cystic fibrosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top